Cumulative incidence of post‐infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis by Nguyen‐Van‐Tam, Jonathan et al.
Influenza Other Respi Viruses. 2020;00:1–9.    |  1wileyonlinelibrary.com/journal/irv
 
Received: 20 December 2019  |  Accepted: 24 May 2020
DOI: 10.1111/irv.12770  
O R I G I N A L  A R T I C L E
Cumulative incidence of post-infection asthma or wheezing 
among young children clinically diagnosed with respiratory 
syncytial virus infection in the United States: A retrospective 
database analysis
Jonathan Nguyen-Van-Tam1 |   Veronique Wyffels2 |   Maartje Smulders3 |   
Debasish Mazumder4 |   Rohit Tyagi4 |   Nikhil Gupta4 |   
Sandra Gavart2 |   Roman Fleischhackl5
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Maartje Smulders was an employee of SmartAnalyst at the time of the study but has since left the company; present address: PrimeVigilance Ltd, Guildford, UK. 
The peer review history for this article is available at https://publo ns.com/publo n/10.1111/irv.12770  
1Health Protection and Influenza Research 
Group, University of Nottingham, 
Nottingham, UK
2Janssen Pharmaceutica NV, Beerse, 
Belgium
3SmartAnalyst, New York City, NY, USA
4SmartAnalyst, Gurgaon, India
5Janssen-Cilag, Vienna, Austria
Correspondence
Roman Fleischhackl, Janssen-Cilag, Vienna, 
Austria.
Email: rfleisch@its.jnj.com
Funding information
Janssen Pharmaceuticals
Abstract
Background: Respiratory syncytial virus (RSV) infection is implicated in subsequent 
development of asthma/wheezing (AW) among term and pre-term infants. We de-
scribe the cumulative incidence of AW among hospitalized and ambulatory neonates/
infants/toddlers following RSV infection diagnosis over three independent follow-up 
periods.
Methods: Between January 1, 2007 and March 31, 2016, patients aged 0-2 years 
old with first clinical diagnosis of RSV infection were identified using the Optum® 
integrated electronic health records and claims database. Patients diagnosed with 
AW ≤ 30 days post-RSV diagnosis were excluded. Three cohorts with 1, 3, and 5 years 
of follow-up were stratified by presence or absence of specific RSV high-risk factors, 
including pre-term birth and pre-defined, pre-existing comorbidities. Descriptive sta-
tistics and logistic regression results were reported.
Results: Overall, 9811, 4524, and 1788 RSV-infected high-risk factor negative pa-
tients were included in 1, 3, and 5-year independent cohorts, respectively. Of these, 
6.5%, 6.9%, and 5.8%, respectively had RSV-related hospitalization. By the end of 
follow-up, 14.9%, 28.2%, and 36.3% had AW events. Overall, 3030, 1378, and 552 
RSV-infected high-risk factor positive patients were included in the respective co-
horts. Of these, 11.4%, 11.1%, and 11.6%, respectively were hospitalized with initial 
RSV infection and 18.1%, 32.9%, and 37.9% had subsequent AW events within the 
follow-up period. Logistic regression confirmed RSV-related hospitalization signifi-
cantly increased the likelihood of developing AW (P < .05) in high-risk factor positive 
and negative patients.
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1  | INTRODUC TION
Acute lower respiratory tract infections (LRTIs) caused by respiratory 
syncytial virus (RSV) infection are a common cause of hospitalization 
in the young, especially in children under 2 years of age. Globally in 
2015, approximately 3.2 million (uncertainty range [UR] 2.7-3.8) hos-
pital admissions, and 59 600 (UR 48 000-74 500) in-hospital deaths 
occurred worldwide due to RSV-related LRTIs in children younger than 
5 years old. In children younger than 6 months, 1.4 million (UR 1.2-1.7) 
hospital admissions and 27 300 (UR 20 700-36 200) in-hospital deaths 
were recorded due to RSV LRTI.1 Studies indicate that among children, 
RSV is the causative pathogen of 50%-90% of hospitalizations due to 
bronchiolitis, 5%-40% of those due to pneumonia, and 10%-30% of 
those due to tracheobronchitis.2,3 In the USA, RSV infection has been 
associated with an estimated 57 527 hospitalizations and 2.1 million 
outpatient visits each year among children aged < 5 years.4
Although RSV infection is self-limiting in most patients, severe 
outcomes and complicated disease are more likely in certain pop-
ulations, for example, infants under 6 months of age, pre-term in-
fants, older adults (≥65 years old), immunocompromised patients, 
and patients with chronic lung or heart disease.5-7 Mortality rates 
associated with RSV infection are generally low in otherwise healthy 
infants (below 1%), but increase significantly in children with bron-
chopulmonary dysplasia (BPD) and congenital heart disease (CHD).7 
A previous study reported a threefold higher mortality rate in chil-
dren with cardiac (3.4%) and lung disease (3.5%).8 Another study 
reported the weighted mean case fatality rate was 1.2% among pre-
term infants; 5.2% among children with CHD; and 4.1% among chil-
dren with BPD. Case fatality estimates among children not at high 
risk ranged from 0% to 1.5%.9
Although wheeze is a key symptom of RSV infection itself, fur-
ther episodes of acute wheezing are reported following RSV LRTI at 
an early age, particularly in the first 2 years of life. These episodes 
mimic early childhood asthma, with persistence of lung function ab-
normalities until adolescence in some patients. This phenomenon 
has been termed post-RSV wheezing disorder.7,10 Some evidence 
also exists that children contracting RSV bronchiolitis within the 
first year of life may be at increased risk of developing asthma later 
in childhood.11 Studies have demonstrated that children hospitalized 
with RSV bronchiolitis during infancy are more likely to have sub-
sequent episodes of wheezing and asthma compared with children 
with RSV bronchiolitis but not hospitalized, particularly in the first 
4 years of life.12
At present, understanding of the post-RSV infection clinical bur-
den of disease in infants and young children, both with and without 
pre-existing high-risk factors, remains limited. Most recent studies 
have focused on premature infants at high risk for asthma/recur-
rent wheezing. In this study, we describe the cumulative incidence 
of post-RSV infection asthma/wheezing (AW) among a large general 
population of children aged 0-2 years (including both high-risk factor 
positive and negative children), after a clinical diagnosis of RSV bron-
chiolitis using an integrated EHR and claims database.
2  | METHODS
2.1 | Study aims and design
We aimed to calculate the cumulative incidence of AW among neo-
nates, infants, and toddlers (aged 0-2 years) after RSV diagnosis over 
separate follow-up periods of 1, 3, or 5 years, using an Integrated 
EHR and claims database. These 3 separate follow-up periods were 
established to compensate for data lost to follow-up and to accu-
rately reflect the true post-RSV infection AW cumulative incidence 
rates in the target population. We explored the a priori hypothesis 
that the cumulative incidence of post-RSV infection AW would be 
different between independent groups of patients: those hospital-
ized with RSV infection vs those managed exclusively via ambulatory 
care.
2.2 | Case records and methodology
This study used integrated de-identified claims and EHR data from 
the Optum Integrated EHR and claims database to identify neo-
nates/infants/toddlers (0-2 years old) diagnosed with RSV infection/
unspecified bronchiolitis between January 1, 2007 and March 31, 
2016. Clinical diagnosis of RSV infection/unspecified bronchiolitis 
was confirmed based on ICD-9 diagnosis codes (including 480.1, 
79.6, 466.11, and 466.19) and ICD-10 diagnosis codes (including 
J12.1, B97.4, J21.0, J20.5, J21.8, and J21.9). Diagnosis codes for AW 
included ICD-9 code 493 and ICD-10 codes J45 and R06.2, with only 
the first ever AW diagnosis considered for this analysis (Table S1). 
The database holds records for over 2.2 million people in the USA 
and is broadly representative of the US population as a whole. 
However, it contains relatively more data from the Mid-West and 
Conclusions: In infants diagnosed with RSV infection, RSV-related hospitalization 
was associated with a significantly increased likelihood of AW development for at 
least 5 years, compared with non-hospitalized patients.
K E Y W O R D S
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virus, wheezing
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less from the West and North-East regions, while the proportion of 
its data from the South region is similar to the national geographical 
distribution. The Optum database has a lower percentage of younger 
patients (7% aged 0-9 years) compared with the US population as a 
whole (13% aged 0-9 years).
2.3 | Study population
Patients with a clinically recognized (ICD-9 or ICD-10 recorded) RSV 
infection diagnosis during hospitalization, emergency room, ambu-
latory, or hospital outpatient visits were identified in the database. 
All patients were required to have at least 1 year of data prior to 
diagnosis (Figure 1). In patients < 12 months of age, data before first 
RSV infection diagnosis were required for a period equivalent to the 
patient's age. Patients with an initial diagnosis of AW ≤ 30 days dur-
ing or after first RSV diagnosis were excluded from the analysis (in-
duction period).
Stratified analyses were undertaken on patients with and with-
out a clinical diagnosis of high-risk factors for AW. High-risk factors 
included pre-term birth, cardiovascular disease (including cere-
brovascular disease, Down's syndrome with CHD, ischemic heart 
disease, peripheral vascular disease, higher risk/lower risk CHD), 
bronchopulmonary disease (asthma, BPD, pneumonia [excluding 
that due to RSV infection], interstitial pulmonary fibrosis of pre-
maturity, Wilson-Mikity syndrome, congenital airway anomalies, 
chronic perinatal respiratory disease), and neuromuscular disease. 
Other high-risk factors included cystic fibrosis, congenital and met-
abolic disease, and kidney disease. Occurrence of ICD codes for 
high-risk factors was identified during the 12 months preceding 
first RSV diagnosis for patients > 1 year of age, except pre-term 
birth which was identified during or after RSV diagnosis. For pa-
tients < 1 year of age, high-risk factor diagnosis was considered at 
any time during their lifetime. Following RSV diagnosis, new devel-
opment of these predefined risk factors was not assessed. For full 
details on factors considered high risk and their diagnosis codes, 
see Table S1.
Hospitalizations were considered RSV-related if the admis-
sion was associated with ICD-9 or ICD-10 codes for RSV infection 
and if the hospitalization occurred during the follow-up period 
(1/3/5 years) at any time before the incidence of AW; this includes 
patients diagnosed in an outpatient setting who were subsequently 
hospitalized with an RSV diagnosis, as well as patients with an initial 
diagnosis of RSV in the hospital setting. Both RSV infection and re-
spiratory plus concurrent RSV diagnosis hospital admission claims 
in the EHR were included. Hospital admissions without RSV diag-
nosis codes were excluded. Severe RSV cases are considered more 
likely to be treated in the hospital than ambulatory patients. For pa-
tients with multiple comorbidities, the order in which diagnoses are 
recorded may differ, therefore, all (primary, secondary, or tertiary) 
diagnosis code positions were used for identification.
2.4 | Statistics
Frequencies (percentages with 95% confidence intervals [95% CI]) 
and means (standard deviation) are reported for categorical (eg, gen-
der, and race) and continuous variables (eg, age) for cohorts with or 
without high-risk factors, respectively. Logistic regression analyses 
were conducted to assess whether patients with a clinical diagno-
sis of RSV infection who were hospitalized had a significantly larger 
likelihood of developing post-RSV infection AW compared with non-
hospitalized patients.
3  | RESULTS
A total of 12 841 patients diagnosed with RSV infection had at least 
1 year of follow-up data, while a further 5902 and 2340 patients had 
3 and 5 years of follow-up data, respectively. Among these groups, 
9811, 4524, and 1788 patients respectively were high-risk factor 
negative and 3030, 1378, and 552 patients respectively were high-
risk factor positive. Attrition of patients throughout the study period 
is described in Figure S1.
F I G U R E  1   Study design diagram. AW, asthma/wheezing; RSV, respiratory syncytial virus
1-y washout period for RSV diagnosis
Washout period for patients <12 mo
equivalent to the patient’s age All patients should have ≥12 mo of
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The demographic characteristics of the patients with 1 year of 
follow-up are summarized in Table 1, with 56.7% males in the high-
risk factor negative patients group and 57.1% males in the high-risk 
factor positive patients group, and an overall mean age of 0.8 years 
at first RSV diagnosis (0.7 years for high-risk factor negative and 
0.8 years for high-risk factor positive patients). By the end of 1 year 
of follow-up, the overall proportion of patients with RSV-related 
hospitalization was 7.7%, while the hospitalization rates by risk 
factor were 6.5% for high-risk factor negative patients and 11.4% 
for high-risk factor positive patients. The majority (>70%) of RSV-
related hospitalizations occurred within the first 2 months following 
initial RSV diagnosis (Figure 2). The other 2 cohorts (3 and 5 years of 
follow-up) showed similar demographic patterns, with similar hos-
pitalization rates according to the presence or absence of high-risk 
factors across both follow-up cohorts (Table S2).
3.1 | Cumulative incidence of post-RSV 
infection AW
Among the 1-year follow-up cohort, 2009 of 12 841 (15.6%) patients 
had an AW diagnosis, including 1462 of 9811 (14.9%) who were high-
risk factor negative and 547 of 3030 (18.1%) who were high-risk fac-
tor positive. For patients with RSV-related hospitalization, 27.5%, 
45.5%, and 54.2% by the end of the 1, 3, and 5 years of follow-up, 
respectively, experienced at least 1 AW event (Figure 3A). The cu-
mulative incidence of post-RSV infection AW was lower among am-
bulatory care only patients (14.7%, 27.9%, and 35.3%, respectively) 
(Figure 3A) compared with patients with RSV-related hospitalization.
A similar pattern of higher post-RSV infection AW incidence in 
hospitalized vs ambulatory patients was observed among high-risk 
factor negative (Figure 3B) and among high-risk factor positive pa-
tients (Figure 3C).
3.2 | Association between hospitalization and 
risk of post-RSV infection AW
Logistic regression analysis indicated that RSV-related hospitaliza-
tion is associated with a significantly increased likelihood of devel-
oping AW among both high-risk factor positive and high-risk factor 
negative RSV-infected patients at each follow-up year, compared 
with RSV infection managed solely in ambulatory care, typically by 
twofold (Table 2). Males also appeared to be at consistently elevated 
likelihood for developing AW, typically 1.5-fold, whereas RSV diag-
nosis in the known RSV season (as opposed to other times of year) 
was associated with a typically 30% lower likelihood of AW (Table 2).
4  | DISCUSSION
We used data from the Optum Integrated EHR and claims database 
to investigate the cumulative incidence of AW among a large popula-
tion of hospitalized and ambulatory neonates, infants, and toddlers 
diagnosed with RSV infection, with and without pre-existing high-
risk factors. Overall, we found that the cumulative incidence of AW 
within 5 years of diagnosis was high in both ambulatory RSV infec-
tion patients (35%) and patients hospitalized with RSV bronchiolitis 
Overall
High-risk factor 
negative (76.4%)
High-risk factor 
positive (23.6%)
All patients 
(n = 12 841) All patients (n = 9811) All patients (n = 3030)
Gender
Male, n (%) 7292 (56.8) 5561 (56.7) 1731 (57.1)
Agea 
Mean (SD) 0.8 (0.9) 0.7 (0.9) 0.8 (0.9)
Median (IQR) 0 (0-2) 0 (0-2) 0 (0-2)
Race
African American, 
n (%)
630 (4.9) 478 (4.9) 152 (5.0)
Asian, n (%) 491 (3.8) 370 (3.8) 121 (4.0)
Caucasian, n (%) 8781 (68.4) 6683 (68.1) 2098 (69.2)
Other/unknown, 
n (%)
2939 (22.9) 2280 (23.2) 659 (21.8)
Hospitalized with 
RSVb , n (%)
983 (7.7) 639 (6.5) 344 (11.4)
Abbreviations: IQR, interquartile range; RSV, respiratory syncytial virus; SD, standard deviation.
aAge at first RSV and or bronchiolitis diagnosis in years. 
bHospitalization during and within the respective follow-up post first RSV diagnosis. 
TA B L E  1   Demographic characteristics 
of patients with RSV infection and 1 year 
of follow-up
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(54%). Results suggest that while severity of RSV infection is a 
marker for AW later in childhood, and severe cases are more likely 
to require hospitalization, milder cases of RSV infection may still be 
associated with post-RSV infection AW. After 1 year of follow-up, in 
RSV-related hospitalized patients the incidence of AW among high-
risk factor positive patients is higher than among high-risk factor 
negative patients. At 5-year follow-up, there was a smaller numerical 
difference in the AW incidence between these 2 groups. This may 
be due to the smaller sample sizes and/or development of high-risk 
factors after RSV diagnosis.
A previous study looked at asthma and wheezing in infants 
following hospitalization due to RSV bronchiolitis.13 This study re-
ported a cumulative prevalence of asthma of 30% in the RSV group 
vs 3% in the control group at age 7 years (P < .001), while the cumula-
tive prevalence of "any wheezing" was 68% and 34% in these groups, 
respectively (P < .001). Asthma was reported during the year prior 
to follow-up in 23% of the RSV group vs 2% of the control group 
(P < .001), while allergic sensitization was found in 41% vs 22% of 
the control group (P = .039). RSV bronchiolitis had the highest in-
dependent risk ratio for asthma (odds ratio [OR]: 12.7) and had a 
significantly elevated independent risk ratio for allergic sensitization 
(OR: 2.4). In addition, a longitudinal cohort study found that in in-
fants and children previously hospitalized with RSV-proven bronchi-
olitis, the prevalence of wheezing was 28.1% vs 13.1% in controls 
at 30-42 months old. At age 69-81 months, this was 22.6% vs 9.6%, 
respectively. The cumulative prevalence of asthma was 38.4% in the 
RSV group and 20.1% in controls at 91 months old.14
Given the association between RSV bronchiolitis and subse-
quent risk for AW, it is plausible that protecting young children with 
vaccines or antibody therapies might also reduce the subsequent 
burden of wheezing disorders in childhood. Palivizumab, a monoclo-
nal antibody, is currently licensed for prevention of RSV infection in 
a limited population. A recently published follow-up of a randomized 
control trial analyzed the effect of palivizumab prophylaxis during 
infancy on asthma and lung function in children aged 6 years. While 
the incidence of parent-reported current asthma was significantly 
decreased in the palivizumab group compared with placebo (14.1% 
vs 24.0%; a 9.9% absolute risk reduction), palivizumab prophylaxis 
had no significant effect on the incidence of current physician-di-
agnosed asthma (10.3% vs 9.9%, risk ratio—0.4) or lung function.15
In contrast, a Japanese observational case-control study in 
children aged 6 years evaluated whether palivizumab could im-
pact subsequent recurring wheeze and atopic asthma. Physician-
diagnosed recurrent wheezing was significantly lower in treated 
infants compared with untreated infants (15.3% vs 31.6%; 
P = .003). However, there was no difference between treated and 
untreated groups in the rate of atopic asthma (15.3% and 18.2%, 
respectively).16
It is difficult to compare the contrasting findings of these studies 
due to differences in study designs, endpoint definitions, and eth-
nic profiles of participants. Taken together, these findings suggest 
prophylactic treatment may be effective in reducing RSV-related 
morbidity in infants. However, palivizumab use is currently limited to 
high-risk patient populations and as such, there is an unmet medical 
F I G U R E  2   Timing of first RSV hospitalization for the cohort of patients with 1 y of follow-up. RSV, respiratory syncytial virus
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F I G U R E  3   Cumulative incidence of AW among hospitalized/ambulatory neonates/infants/toddlers after RSV/bronchiolitis infection 
diagnosis in the Optum Integrated Electronic Health Records and claims database. AW, asthma/wheezing; RSV, respiratory syncytial virus
(A) Overall (high-risk-factor positive and negative)
5-y follow-up
(N1 = 168)
(N2 = 2172)
Hospitalized
33.3%
15.4%
26.4%
14.6%
44.6%
23.0%
47.6%
28.9%
49.4%
31.9%
54.2%
35.3%
38.8%
22.5%
45.5%
27.9%
27.5%
14.7%
Not hospitalized
0-y 1-y 2-y 3-y 4-y 5-y
3-y follow-up
(N1 = 466)
(N2 = 5436)
1-y follow-up
(N1 = 983)
(N2 = 11 858)
(B) High-risk-factor negative 
5-y follow-up
(N1 = 104)
(N2 = 1684)
33.7%
15.5%
24.6%
14.2%
45.2%
23.0%
49.0%
28.6%
51.9%
31.5%
57.7%
35.0%
37.1%
22.0%
45.0%
27.0%
25.5%
14.2%
0-y 1-y 2-y 3-y 4-y 5-y
3-y follow-up
(N1 = 313)
(N2 = 4211)
1-y follow-up
(N1 = 639)
(N2 = 9172)
(C) High-risk-factor positive
5-y follow-up
(N1 = 64)
(N2 = 488)
32.8%
15.0%
30.1%
15.8%
43.8%
23.0%
45.3%
29.9%
45.3%
33.2%
48.4%
36.5%
42.5%
24.5%
46.4%
31.2%
31.1%
16.4%
0-y 1-y 2-y 3-y 4-y 5-y
3-y follow-up
(N1 = 153)
(N2 = 1225)
1-y follow-up
(N1 = 344)
(N2 = 2686)
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need for the development of simpler RSV treatments which protect 
the more generalized population of infants from severe RSV infec-
tion and associated complications, such as AW.
In our study, RSV diagnosis in the RSV season was associated 
with a typically 30% lower likelihood of AW compared with other 
times of year (Table 2). This may indicate that RSV diagnosis out-
side the known RSV season carries a higher risk of AW, possibly due 
to patients being more susceptible to RSV at this time—this result 
would require further investigation before any conclusions may be 
drawn.
As with any such study, our study has a number of limitations, 
most notably its retrospective, observational nature which means 
that it is not possible to infer cause and effect between hospital-
ization and AW risk. In addition, the study was designed to evalu-
ate patients with a first-time diagnosis of RSV or AW; however, it 
does not include recurrent AW episodes which are well recognized 
in other studies.17,18 It is also not possible to determine the atopic 
status of the infants/children studied using Optum. The database 
has a lower percentage of younger patients than the US popula-
tion as a whole; therefore, the study population may be under-rep-
resented. While it is possible that RSV-infected patients may not 
have been adequately captured in the database, it is reasonable to 
expect that any such under-representation would be consistent 
across all the study cohorts.
Another issue relating to the study methodology is that RSV 
diagnosis was identified by the appearance of an RSV/bronchiol-
itis ICD-9 or ICD-10 code on a medical claim or record. Thus, some 
bronchiolitis patients may not have had RSV infection, as bronchi-
olitis could have been caused by another etiologic agent. Although 
RSV infection is the most common cause of bronchiolitis, approx-
imately one-third of cases can be caused by another viral patho-
gen.19,20 A recent study21 reported that RSV-specific ICD-10 codes 
may underestimate the number of actual RSV infections and sug-
gested that a combination of RSV-specific and general acute LRTI 
ICD-0 codes may be more accurate; therefore, our approach could 
possibly underestimate the true burden of RSV. Also, in Optum, a 
medical record does not indicate that an RSV diagnostic test was 
performed in that setting and diagnosis may have instead been 
based on symptoms, risk factors, and seasonality only. RSV labo-
ratory test results in the database were not comprehensively re-
corded and therefore were not used for RSV patient identification. 
Additionally, as high-risk factors were only assessed before first 
TA B L E  2   Odds ratios for risk of developing AW among hospitalized/ambulatory neonates/infants/toddlers after RSV/bronchiolitis 
infection diagnosis, in the Optum Integrated Electronic Health Records and claims database
High-risk factor negative High-risk factor positive
1-y follow-up 3-y follow-up 5-y follow-up 1-y follow-up 3-y follow-up
5-y 
follow-up
RSV hospitalizationa  (yes vs no)
Odds ratio 2.1 2.3 2.7 2.4 2.0 1.7
Confidence interval 1.8-2.6 1.8-2.9 1.8-4.0 1.8-3.0 1.4-2.8 1.0-3.0
P value <.0001 <.0001 <.0001 <.0001 <.0001 .0433
RSV diagnosis in RSV season (yes 
vs no)
Odds ratio 0.7 0.7 0.6 0.7 0.7 0.8
Confidence interval 0.6-0.8 0.6-0.8 0.5-0.8 0.6-0.9 0.5-1.0 0.5-1.3
P value <.0001 <.0001 <.0002 .0083 .0264 .3388
Gender (male vs female)
Odds ratio 1.5 1.5 1.5 1.4 1.3 1.7
Confidence interval 1.3-1.7 1.3-1.7 1.2-1.8 1.2-1.7 1.0-1.6 1.2-2.5
P value <.0001 <.0001 <.0002 <.0007 .0311 .0036
Caucasian (yes vs no)
Odds ratio 0.9 0.8 0.9 0.9 0.9 1.0
Confidence interval 0.8-1.0 0.7-0.9 0.7-1.1 0.7-1.1 0.7-1.2 0.7-1.5
P value .0069 .0049 .1949 .3836 .6169 .8096
Prior palivizumab use (yes vs no)
Odds ratio - - - 1.2 1.1 1.6
Confidence interval - - - 0.8-1.7 0.7-1.7 0.8-3.3
P value - - - .4187 .643 .1866
Abbreviations: AW, asthma/wheezing; FU, follow-up; RSV, respiratory syncytial virus.
aHospitalization during and within the respective follow-up post first RSV diagnosis. 
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RSV diagnosis, the impact of any newly emerging high-risk factors 
cannot be evaluated. Patients hospitalized with RSV infection may 
have been more likely to visit a hospital specialist than a primary 
care physician for any subsequent AW; hospital specialist visits are 
not captured in the Optum database.
However, an important strength of the use of the Optum 
Integrated EHR and claims database in relation to the current study 
is that it contains linked data on the whole patient journey, encom-
passing ambulatory, and hospital care.
In summary, this large population database study has provided 
further evidence of the incidence of AW among neonates, infants, 
and toddlers after RSV infection. We have identified an increased 
likelihood of developing AW among RSV-infected patients who were 
hospitalized compared with patients managed exclusively in ambu-
latory care. To reduce the burden of wheezing disorders in children, 
efforts should be directed toward finding new vaccines to prevent 
RSV infection and developing antiviral therapies to prevent severe 
disease, early diagnosis, and interventions which reduce the risk of 
RSV severity.
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